This biomarker is also known as:
- G-protein coupled receptor 105,
- G protein-coupled receptor 105,
- P2Y14 receptor,
- P2Y purinoceptor 14,
- P2Y(14) receptor,
- UDP-glucose receptor,
- G protein coupled receptor for UDP-glucose,
- purinergic receptor P2Y, G-protein coupled, 14,
View in BioMuta
P2RY14, or GPR105, is a G-protein coupled receptor that responds to extracellular purine and pyrimidine nucleotides. P2RY14 is not activated by ATP, ADP, UTP or ATP, but is a receptor for UDP-glucose and other UDP-sugars coupled to G-proteins. P2RY14 is thought to be involved in extending the known immune system functions of P2Y receptors by participating in the regulation of the stem cell compartment, and it may also play a role in neuroimmune function. Two transcript variants encoding the same protein have been identified for this gene. There are two transcript variants for this gene that result in the same protein.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional ovarian data available.
P2RY14 (GPR105) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. P2RY14 was not in the group of 13 selected for further validation.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.